UNICA IRIS Institutional Research Information System

SERPE, ROBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 101.620
NA - Nord America 6.228
AS - Asia 2.530
SA - Sud America 405
AF - Africa 64
Continente sconosciuto - Info sul continente non disponibili 7
OC - Oceania 6
AN - Antartide 1
Totale 110.861
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 99.877
US - Stati Uniti d'America 6.145
CN - Cina 1.004
SG - Singapore 906
UA - Ucraina 497
SE - Svezia 375
BR - Brasile 313
DE - Germania 256
VN - Vietnam 224
FI - Finlandia 176
GB - Regno Unito 174
FR - Francia 129
HK - Hong Kong 75
KR - Corea 64
IN - India 55
CA - Canada 49
AR - Argentina 38
BD - Bangladesh 27
TR - Turchia 25
PK - Pakistan 23
RU - Federazione Russa 22
ZA - Sudafrica 21
IQ - Iraq 19
BE - Belgio 18
IR - Iran 16
MX - Messico 16
PL - Polonia 16
ES - Italia 15
EC - Ecuador 14
ID - Indonesia 14
JP - Giappone 14
PH - Filippine 14
KE - Kenya 12
NL - Olanda 11
CO - Colombia 10
MA - Marocco 10
IE - Irlanda 9
AT - Austria 8
SA - Arabia Saudita 8
EG - Egitto 7
EU - Europa 7
RS - Serbia 7
VE - Venezuela 7
AU - Australia 6
BG - Bulgaria 6
JO - Giordania 6
TN - Tunisia 6
BO - Bolivia 5
CH - Svizzera 5
CL - Cile 5
PE - Perù 5
UY - Uruguay 5
UZ - Uzbekistan 5
DO - Repubblica Dominicana 4
JM - Giamaica 4
LT - Lituania 4
RO - Romania 4
CR - Costa Rica 3
KG - Kirghizistan 3
KZ - Kazakistan 3
LB - Libano 3
MY - Malesia 3
PY - Paraguay 3
TH - Thailandia 3
AE - Emirati Arabi Uniti 2
AM - Armenia 2
DZ - Algeria 2
GT - Guatemala 2
IL - Israele 2
LA - Repubblica Popolare Democratica del Laos 2
NI - Nicaragua 2
PA - Panama 2
AL - Albania 1
AQ - Antartide 1
AZ - Azerbaigian 1
BW - Botswana 1
BY - Bielorussia 1
EE - Estonia 1
GA - Gabon 1
GQ - Guinea Equatoriale 1
HU - Ungheria 1
IS - Islanda 1
KH - Cambogia 1
KW - Kuwait 1
LU - Lussemburgo 1
ME - Montenegro 1
MK - Macedonia 1
ML - Mali 1
MM - Myanmar 1
MO - Macao, regione amministrativa speciale della Cina 1
NG - Nigeria 1
NO - Norvegia 1
NP - Nepal 1
PR - Porto Rico 1
PS - Palestinian Territory 1
PT - Portogallo 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TW - Taiwan 1
Totale 110.861
Salva come PNG Salva come JPEG
Città #
Cagliari 98.214
Uta 1.364
Woodbridge 599
Fairfield 576
Ashburn 482
Singapore 448
Dallas 399
Houston 399
Chandler 390
Ann Arbor 316
Jacksonville 285
Nyköping 268
Boardman 253
Wilmington 250
Seattle 237
Beijing 227
San Jose 225
Dearborn 171
Cambridge 168
Helsinki 96
Los Angeles 94
Nanjing 86
Ho Chi Minh City 80
Boston 79
Lauterbourg 73
New York 70
Hefei 68
Hong Kong 66
Santa Clara 65
Seoul 57
Shanghai 57
The Dalles 49
Hanoi 45
San Diego 44
Nanchang 35
Buffalo 34
Milan 34
Munich 32
Redwood City 32
Guangzhou 29
Changsha 28
Tianjin 24
Toronto 24
São Paulo 23
Hebei 22
Shenyang 22
Jinan 20
London 20
Verona 19
Brussels 16
Redondo Beach 16
Council Bluffs 15
Norwalk 15
Mountain View 14
Orange 14
Warsaw 14
Zhengzhou 14
Atlanta 13
Auburn Hills 13
Frankfurt am Main 13
Orem 13
Tokyo 13
Baghdad 12
Chennai 12
Chicago 11
Nairobi 11
Jiaxing 10
Phoenix 10
Rome 10
Sassari 10
San Francisco 9
Wuhan 9
Brooklyn 8
Da Nang 8
Dong Ket 8
Dublin 8
Hangzhou 8
Johannesburg 8
Rio de Janeiro 8
Shenzhen 8
Thái Nguyên 8
Augusta 7
Campinas 7
Haiphong 7
Manchester 7
Montreal 7
Nuremberg 7
Nürnberg 7
Pune 7
San Mateo 7
Stockholm 7
Amsterdam 6
Ankara 6
Bielefeld 6
Columbus 6
Curitiba 6
Denver 6
Dhaka 6
Düsseldorf 6
Karachi 6
Totale 107.181
Salva come PNG Salva come JPEG
Nome #
High-density lipoprotein contribute to G0-G1/S transition in Swiss NIH/3T3 fibroblasts 4.967
Morningness Eveningness Questionnaire (MEQ) and salivary DLMO determination: a reliable method of evaluation for circadian pattern 3.724
Effects of an adapted physical training on functional status, body composition and quality of life in persons with spinal cord injury paraplegia: a pilot study 3.431
Krill Oil supplementation modifies endocannabinoid congeners profile in cachectic advanced cancer patients 3.331
Antimicrobial sulfonamides clear latent Kaposi sarcoma herpesvirus infection and impair MDM2-p53 complex formation 3.292
Cardiovascular effects, body composition, quality of life and pain after a Zumba® fitness program in Italian overweight women 2.965
Effects of a nordic walking program on motor and non-motor symptoms, functional performance and body composition in patients with Parkinson's disease 2.762
Antimicrobial sulfonamides inhibit Herpesvirus 8 latency by impairing the MDM2-p53 complex formation 2.696
Positive effects of Nordic Walking on anthropometric and metabolic variables in women with type 2 diabetes mellitus 2.695
Sulfonamide compounds inhibit latent Human Herpesvirus 8 replication by interfering with MDM2-p53 complex formation 2.540
Randomized phase III clinical trial of a combined treatment with carnitine plus celecoxib +/- megestrol acetate for patients with cancer-related anorexia/cachexia syndrome 2.427
Effects of an adapted physical activity program on motor and non-motor functions and quality of life in patients with Parkinson's disease 2.363
null 2.211
The cachexia score (CASCO) as a tool for staging cachectic cancer patients 2.195
Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity 2.188
Validation of the CAchexia SCOre (CASCO). Staging cancer patients: The use of miniCASCO as a simplified tool 2.078
Relationship of morningness-eveningness questionnaire score to Melatonin DLMO measured from saliva sample: circadian patterns of a normal subjects group and a delayed phase syndrome 2.075
Trastuzumab-based adjuvant chemotherapy for breast cancer: Early myocardial dysfunction detected by "speckle tracking" echocardiography (STE). 2.074
null 1.987
Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia 1.871
Krill oil to improve blood lipids status in advanced cancer patient with cachexia 1.774
Efficacy and safety of a two drug-combination regimen for cancer-related cachexia in the clinical practice. 1.728
Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia 1.713
Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results 1.702
null 1.699
Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy 1.685
Persistence, up to 18 months of follow-up, of epirubicin-induced myocardial dysfunction detected early by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.668
Interleukin-1B (IL1B) and interleukin-6 (IL6) gene polymorphisms are associated with risk of chronic lymphocytic leukaemia 1.666
Production of inflammatory molecules in peripheral blood mononuclear cells from severely glucose-6-phosphate dehydrogenase-deficient subjects 1.585
L-Carnitine: An adequate supplement for a multi-targeted anti-wasting therapy in cancer 1.520
Cardioprotective effect of telmisartan in cancer patients treated with telmisartan 1.504
Early epirubicin-induced myocardial dysfunction revealed by serial tissue Doppler echocardiography: correlation with inflammatory and oxidative stress markers 1.482
Trastuzumab-induced early cardiac dysfunction assessed by speckle tracking echocardiography: correlation with chronic inflammation and oxidative stress markers 1.463
Assessment of adiponectin and leptin as biomarkers of positive metabolic outcomes after lifestyle intervention in overweight and obese children 1.365
null 1.362
EFFICACY AND SAFETY OF A TWO DRUG-COMBINATION REGIMEN FOR CANCER-RELATED CACHEXIA IN THE CLINICAL PRACTICE 1.324
null 1.063
Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress 835
Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters 802
Association of serum IL-6 levels with comprehensive geriatric assessment variables in a population of elderly cancer patients 798
Cardioprotective effect of telmisartan in cancer patients treated with epirubicin 784
A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress 780
Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment 779
A PHASE II STUDY WITH ANTIOXIDANTS, BOTH IN THE DIET AND SUPPLEMENTED, PHARMACO-NUTRITIONAL SUPPORT,PROGESTAGEN AND ANTI-COX-2 SHOWING EFFICACY AND SAFETY IN PATIENTS WITH CANCER-RELATED ANOREXIA-CACHEXIA AND OXIDATIVE STRESS 778
null 768
Current medications for cancer cachexia 740
Formoterol and cancer muscle wasting in rats: Effects on muscle force and total physical activity 736
Antioxidant agents alpha lipoic acid, N-Acetyl cysteine and MESNA (2-mercaptoethane sulfonate) are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients 735
Early epirubicin-induced myocardail dysfunction revealed by serial tissue doppler echocardiography (TDI). Correlation with inflammatory and oxidative stress markers 733
Cardioprotective effect of Telmisartan in cancer patients treated with Epirubicin 716
Cancer cachexia: Physical activity and muscle force in tumour-bearing rats 710
null 709
Early epirubicin (EPI)-induced myocardial dysfunction revealed by serial tissue doppler imaging (TDI): Correlation with inflammatory and oxidative stress markers 695
null 694
Muscle wasting in cancer and ageing: Cachexia versus sarcopenia 680
Improvement of physical activity as an alternative objective variable to measure treatment effects of anticachexia therapy in cancer patients 673
The cachexia score (CASCO): a new tool for staging cachectic cancer patients 663
Randomised Phase III Clinical Trial of a Combined Treatment With Carnitine plus Celecoxib +/- Megestrol Acetate for Patients With Cancer-related Anorexia/cachexia Syndrome 654
Megestrol acetate: Its impact on muscle protein metabolism supports its use in cancer cachexia 583
null 572
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 556
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 554
Antioxidant therapy for the treatment of oxidative stress associated to cancer and cancer-related anorexia/cachexia 541
Phase II study with antioxidants, both in the diet and supplemented pharmaco-nutritional support, progestagen and anti-cox-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 529
A phase II study with antioxidants, both in the diet an supplemented, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia-cachexia and oxidative stress 517
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 515
Cancer related anorexia/cachexia (CACS) and oxidative stress: an innovative approach beyond current treatment 511
Correlation between both serum osteopontin/osteonectin and bone remodelling parameters, inflammatory/metabolic variables and survival in metastatic cancer patients with tumors at different sites 496
Prevention of head and neck squamous cell carcinoma. Integrated treatment approach with diet, pharmaco-nutritional support, antioxidants, and cis-retinoic acid. A phase II study. 487
Phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS). and oxidative stress (OS) 487
Effects Of An Adapted Physical Training On Functional And Psycho-physical Status In Patients With Spinal Cord Injury 481
null 465
Prevention of head and neck squamous cell carcinoma. integrated treatment approach with diet, pharmaco-nutritional support, antioxidants (and anti-COX-2): preliminary results of a phase II study 455
null 450
An innovative approach to CACS 449
null 413
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutrional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: interim results 411
Efficacy of L-carnitine administration on fatigue, quality of life and nutritional status in 12 advanced cancer patients undergoing anticancer therapy 408
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 407
null 390
null 342
An innovative treatment approach for cancer-related anorexia/cachexia and oxidative stress: Background and design of an ongoing, phase III, randomized clinical trial 327
Randomised phase III clinical trial to evaluate the efficacy and safety of an integrated treatment (diet, pharmaco-nutritional and pharmacological) in cancer patients with cancer-related anorexia/cachexia and oxidative stress: Interim results 324
Impact of a two-drug combination regimen for cancer-related cachexia on nutritional, anabolic/metabolic, physical activity, anti-infammatory and quality of life variables 314
null 304
Curcuma Longa extract is effective in improving inflammatory status and redox balance in patients with cancer-related cachexia and oxidative stress 304
MESNA (2-mercaptoethane sulfonate) is effective in inducing lymphocyte progression through cell cycle in patients with advanced cancer of different sites 303
null 267
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS): Interim results 264
Randomised phase III clinical trial of 5 different arms of treatment for patients with cancer-related anorexia/cachexia syndrome (CACS) 244
null 208
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS). A phase III randomised clinical trial 207
Prognostic role of lipid profile in patients with advanced cancer 206
An innovative treatment approach for cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 198
A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia (CACS) and oxidative stress (OS) 149
null 147
Cancer related anorexia/cachexia and oxidative stress: A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 147
Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia 142
Cancer-related anorexia/cachexia (CACS) and oxidative stress (OS): A phase II study with antioxidants, pharmaco-nutritional support, progestagen and anti-COX-2 139
Focus on the assessment of physical activity level of patients with cancer cachexia enrolled in a randomized phase III clinical trial 132
Totale 110.982
Salva come PNG Salva come JPEG
Categoria #
all - tutte 143.415
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 143.415
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20212.720 0 0 0 0 0 0 0 0 0 1.152 1.027 541
2021/20224.262 401 314 179 296 465 341 175 187 353 439 550 562
2022/20235.508 491 659 689 447 465 528 254 459 355 379 464 318
2023/20246.816 445 336 335 511 693 1.312 839 473 311 467 584 510
2024/20258.457 1.040 1.647 1.329 1.267 700 1.116 564 104 185 126 184 195
2025/20264.131 300 238 677 435 347 310 717 219 358 530 0 0
Totale 111.059